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Recent  advances  in  the  ﬁeld  of  immunometabolism  support  the  concept  that  fundamental  processes  in
T cell  biology,  such  as TCR-mediated  activation  and  T helper  lineage  differentiation,  are  closely  linked
to  changes  in  the  cellular  metabolic  programs.  Although  the  major  task  of  the  intermediate  metabolism
is  to provide  the  cell  with  a constant  supply  of energy  and molecular  precursors  for the production
of  biomolecules,  the  dynamic  regulation  of  metabolic  pathways  also  plays  an  active  role  in shaping  T
cell  responses.  Key  metabolic  processes  such  as  glycolysis,  fatty  acid  and  mitochondrial  metabolism
are  now  recognized  as crucial  players  in  T cell activation  and  differentiation,  and  their  modulation  can
differentially  affect  the  development  of  T  helper  cell  lineages.  In this  review,  we  describe  the  diverselycolysis
atty acid metabolism
TOR
MPK
CC
metabolic  processes  that  T cells engage  during  their  life  cycle  from  naïve  towards  effector  and  memory
T  cells.  We  consider  in  particular  how  the  cellular  metabolism  may  actively  support  the function  of  T
cells  in  their  different  states.  Moreover,  we  discuss  how  molecular  regulators  such  as mTOR  or  AMPK  link
environmental  changes  to adaptations  in the  cellular  metabolism  and  elucidate  the  consequences  on T
cell differentiation  and  function.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
T cells arise in the thymus in a naïve state and migrate to periph-
ral sites, patrolling for their cognate antigen. Until receiving this
ignal, naïve T cells are quiescent and largely metabolically inactive.
ollowing T cell receptor (TCR) stimulation, T cells rapidly divide
nd acquire effector functions. Whether a cell becomes a T effector
ell (Teff) or T regulatory cell (Treg) depends on the conditions in
hich the stimulation took place. The resulting proliferation and
ffector functions of specialized T cells demands a metabolic shift
rom the previously quiescent state, a process commonly referred
o as metabolic reprogramming. Once the antigen load is reduced,
he lack of stimulus for Teff cells leads to their apoptosis [1], except
or a small number of cells that become memory T cells [2,3]. With-
ut permanent antigen stimulation, a memory T cell has – similar
o a naïve T cell – much lower energetic requirements than its
ctivated counterpart.
While it is evident that the energetic and biosynthetic demands
f quiescent and highly proliferating cytokine producing T cells are
ery different, recent studies support the concept that metabolism
s not merely a passive phenomenon that supports T cell acti-
ation, but also critically inﬂuences the different types of T cell
esponses. Understanding how speciﬁc metabolic processes inﬂu-
nce T cell differentiation and function, may  offer novel therapeutic
pproaches in the clinic, with impact on autoimmunity, infection
nd cancer. In order to exploit the potential of immunometabolism
or therapy, we need not only a thorough knowledge of the bio-
hemical reactions that T cells engage during their life cycle, but
lso a deep insight into the molecular mechanisms by which
etabolism shapes and controls T cell development and function.
n this review, we provide an overview on the most important
ntermediate metabolic pathways in T cell subsets. We  furthermore
iscuss the impact of key metabolic pathways such as glycolysis as
ell as fatty acid synthesis and the mitochondrial metabolism on T
ell activation and proliferation. The importance of major hubs of
etabolic regulation (mTOR, and AMPK) in activation and T helper
ell differentiation will also be explored. Finally, as a prominent
xample of how metabolism can be therapeutically exploited, we
escribe the impact of fatty acid metabolism on T cell differenti-
tion and how inhibition of ACC1 activity can promote tolerance
nder conditions of autoimmune inﬂammation.
. Cellular metabolism in a nutshell
.1. Glycolysis and the tricarboxylic acid cycle
The term glycolysis describes a series of cytosolic enzy-
atic reactions that generate pyruvate from glucose. After being
mported from the extracellular space by specialized transporters
such as Glut1), glucose is irreversibly converted to glucose-6-
hosphate (G6P) by the action of hexokinase and further degraded
n the cytosol to pyruvate. One major metabolic fate of pyruvate
s the import into the mitochondria and consequent conversion
o acetyl-CoA, entering the tricarboxylic acid (TCA) cycle (Fig. 1A)
o produce NADH and FADH2, which can be subsequently used
o generate ATP in the electron transport chain (ETC) (described
elow in detail). Throughout glycolytic and TCA reactions, sev-
ral intermediates are formed, which can also be used in different
iosynthetic pathways, such as the pentose phosphate pathway
PPP), serine biosynthesis, de novo fatty acid synthesis (FAS) and
exosamine biosynthesis (Fig. 1A). Accordingly, glycolysis should
ot only be considered as a mere energy-generating pathway, but
lso a metabolic route for anabolic biosynthetic reactions.
Alternatively to being imported into the mitochondria, pyruvate
an also be converted to lactate in the cytosol by the enzyme lactateunology 28 (2016) 514–524 515
dehydrogenase (LDH). This process regenerates the NAD+ which is
consumed during the generation of pyruvate from glucose. This
strategy gains importance for example under hypoxic conditions,
when NAD+ cannot be regenerated from NADH during the reactions
of the ETC in the mitochondria. Without lactate generation, NAD+
pools would drop and glycolytic reactions requiring NAD+ as a co-
factor would be limited (Fig. 1A). Hence, the pyruvate to lactate
reaction allows the cells to metabolize glucose in a mitochondria-
independent manner. Interestingly, large amounts of lactate can
also be produced in the presence of oxygen, a phenomenon known
as aerobic glycolysis or Warburg effect. This speciﬁc metabolic phe-
notype has been observed in tumor cells and more recently, also in
lymphocytes [4–7], although its biological relevance is not yet fully
understood.
2.2. Oxidative phosphorylation
Inside the mitochondria, NADH and FADH2 generated during
glycolysis and/or the TCA cycle are regenerated back to their oxi-
dized forms (NAD+ and FAD) by the ETC, which consists of a series of
transmembrane proteins that are present on the inner mitochon-
drial membrane (IMM). The ﬁrst two complexes (I and II) of the
ETC carry out the oxidation of NADH and FADH2, respectively, and
donate the electrons along the chain, ﬁrst to complex III and ﬁnally
to complex IV, where they are transferred to molecular oxygen,
generating water [8]. This electron transfer occurs concomitantly
with the transfer of protons to the intermembrane space of the
mitochondria, thereby creating a differential of electrical charges
between both sides of the membrane. ATP synthase (the last pro-
tein of the ETC) ﬁnally resolves this gradient by pumping protons
back to the mitochondrial matrix and coupling this process to the
phosphorylation of ADP to ATP. This process, also designated as
oxidative phosphorylation (OXPHOS), ensures the optimal transfer
of the energy that is stored in a molecule such as glucose into cellu-
lar ATP. Full oxidation of the NADH and FADH2 that are generated
in the TCA can result in a total gain of 30–36 ATP molecules from 1
molecule of glucose and 106 ATP from 1 molecule of palmitate but
requires the presence of molecular oxygen as an electron acceptor
during ETC reactions [9] (Fig. 1B).
2.3. Fatty acid metabolism and cholesterol synthesis
One of the fates of acetyl-CoA generated during glycolysis is
de novo FAS. In the mitochondria, acetyl-CoA condensation with
oxaloacetate generates citrate, which can be then exported to the
cytosol where the reverse reaction, the reconversion to acetyl-
CoA, takes place. The ﬁrst committed step of FAS begins with the
carboxylation of this cytosolic form of acetyl-CoA by the enzyme
acetyl-CoA Carboxylase 1 (ACC1), generating malonyl-CoA (Fig. 1A.)
The next step is performed by fatty acid synthase (FASN), a mul-
tienzyme complex that catalyzes the condensation of acetyl-CoA
and malonyl-CoA to generate longer acyl chains. In a stepwise pro-
cess that depends on NADPH availability, further acetyl molecules
are added to the growing acyl-chain by FASN. The end product
palmitate can later be used as a precursor to form other fatty acids,
more complex lipids such as phospholipids, or as a substrate for the
acylation of proteins [10,11]. Alternatively, two  molecules of acetyl-
CoA can also form acetoacetyl-CoA, initiating cholesterol synthesis
in the cytosol. This step is catalyzed by acetoacetyl-CoA thiolase
(ACAT). A series of NADPH and ATP-consuming steps leads to the
formation of cholesterol, which can then be incorporated into cell
membranes.While FAS is an anabolic process that supports cell proliferation,
fatty acids can be used as an energy source in a catabolic process,
designated as fatty acid ß-oxidation (FAO). To this aim, fatty acids
are transported into the mitochondria by a speciﬁc carrier system,
516 L. Almeida et al. / Seminars in Immunology 28 (2016) 514–524
Fig. 1. Simpliﬁed representation of metabolic pathways activated during TCR signaling. A: TCR stimulation induces the expression of several metabolic genes, increasing
glucose and glutamine import from the extracellular space. Glucose is degraded in the cytosol to pyruvate, which can then be converted to lactate and regenerate the NAD+
that was consumed in the generation of pyruvate. Alternatively, pyruvate can also be imported into mitochondria and decarboxylated to acetyl-CoA, feeding into the TCA
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hich includes the two isoforms of carnitine palmitoyltransferase
CPT) 1 and 2, present on the outer and inner mitochondrial mem-
rane, respectively. Once inside the mitochondria, long-chain fatty
cids are degraded in a series of enzymatic reactions that shorten
he fatty acyl chain down to acetyl-CoA, thereby producing NADH
nd FADH . Fatty acid-derived acetyl-CoA can enter the TCA cycle2
or further oxidation, while the NADH and FADH2 that are gener-
ted can be used as electron donors for the ETC.ermediates can also be used as building blocks in biosynthetic pathways. B: The
the ETC, which consists of a series of transmembrane proteins that are present on
The interplay and balance between the above mentioned
metabolic pathways and routes underlies lymphocyte activation
and differentiation, as we will discuss in the following chapters.
3. Naïve T cells display a metabolic quiescent phenotypeIn the absence of antigen, naïve T cells are maintained by IL-
7, which supports their homeostatic proliferation and survival
[12,13]. In terms of their metabolic activity, naïve T cells remain in a
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uiescent state, since these cells do neither undergo clonal division
or secrete signiﬁcant amounts of cytokines. Therefore, naïve T cells
ave a limited requirement for the induction of anabolic pathways
eeded for the de novo generation of DNA, lipids and proteins. With-
ut the need to spare nutrient-derived carbons for biomolecule
roduction, naïve T cells mainly use the available nutrients to max-
mize energy production though OXPHOS (reviewed in [14]). In
his way, fatty acids and glucose can be fully oxidized to reach an
ptimal yield of ATP.
. T cell activation requires the orchestration of signaling
athways and metabolic reprogramming
Upon antigen recognition, CD4+ and CD8+ naïve T cells become
ighly proliferative and differentiate into Teff cells that exert their
unction as CD4+ T helper (Th) cells, such as Th1, Th2 or Th17
r as CD8+ cytotoxic T lymphocytes (CTL), respectively. Not sur-
risingly, T cell activation requires a metabolic reprogramming
hat supports this highly proliferative and biosynthetic pheno-
ype. [15,16]. In accordance, after TCR-mediated stimulation the
xpression of glycolysis and glutaminolysis-associated genes is
pregulated, including the expression of transporters for extra-
ellular nutrients such as glucose, glutamine and amino acids
15,17,18]. Additionally, the ﬂux through glycolysis, PPP and the
exosamine pathway also increases [15]. The PPP generates ribose-
-phosphate (R5P), which is a precursor for nucleotide synthesis
19] and NADPH, a co-factor necessary in many reactions, such as
ipid synthesis and glutathione recycling. The hexosamine pathway
enerates UDP-N-acetylglucosamine (UDP-GlcNac), used for post-
ranslational modiﬁcations of proteins, a process which was found
o be fundamental for the generation of single-positive thymocytes
uring T cell development and CD8+ T cell proliferation after in vitro
ctivation [20].
A critical prerequisite for metabolic reprogramming upon T cell
ctivation is the integration of early signaling events that allow the
ell to strongly increase the uptake of nutrients, especially glucose.
n 2002, Frauwirth et al. showed that TCR activation together with
D28-mediated co-stimulation induced the activation of the phos-
hatidylinositol 3′-kinase (PI3 K)-Akt signal transduction pathway,
eading to the rapid upregulation of the glucose transporter Glut1
n human peripheral blood T cells [16]. In addition to the increase
n Glut1 expression, Akt was shown to promote Glut1 trafﬁcking to
he cell membrane [21]. Without Glut1, Teff cells have an impaired
apacity to proliferate both in vitro and in vivo [18]. Interestingly,
lut1 deletion seemed to only interfere with T cell differentiation
nto Th1, Th2 and Th17, while CTLs and Tregs were not affected
18]. In the case of CTLs, recent proteomic data obtained using
igh-resolution mass spectrometry indicates that Glut1 and Glut3
rotein levels are comparable [22]. It is therefore possible that CTLs
nd Tregs compensate the loss of Glut1 by their ability to use alter-
ative glucose transporters to cover their glucose supply.
Mitogen-activated protein kinases downstream of TCR/CD28
timulation also appear to directly link T cell stimulation to the
nduction of glycolysis. P38, and specially ERK were necessary to
ully induce expression of hexokinase, the enzyme catalyzing the
rst committed step of glycolysis [23]. In addition, the transcrip-
ion factors Myc  and Hypoxia-inducible factor 1 (Hif1 – known
o regulate cellular metabolism during hypoxia [24]) also seem to
romote metabolic reprogramming after T cell activation [15]. Both
amoxifen-induced ablation of Myc  as well as genetic-deletion of
if1 severely limited the upregulation of the glycolytic programn T cells [15,25]. Yet, when ablation of Hif1 was  induced during
ctivation, there was no defect in metabolic adaptation. Instead, a
ild impairment of glycolysis was seen only at later time points,
ndicating that Hif1 may  play a role in stabilizing optimal glycoly-unology 28 (2016) 514–524 517
sis rates at later stages rather than during early activation steps [15].
Myc  and Hif1 have been reported to be under the control of the
mechanistic target of rapamycin (mTOR) complex [26–29]. mTOR
is a protein kinase that acts as a central integrator of various envi-
ronmental cues and is able to regulate multiple cellular processes
accordingly [30–34]. Among them are autophagy, glucose uptake
and consumption (glycolysis) and the control of protein and lipid
synthesis, all processes which are central during T cell activation
[35,36].
4.1. Activated T cells engage aerobic glycolysis
Intriguingly, the majority of the carbons derived from the glu-
cose that is taken up by T cells following activation is not used as
precursor for anabolic pathways, but instead secreted as lactate
[37–39], even though the cells are not under hypoxic conditions. A
common notion in the immunometabolism ﬁeld is that shifting the
cellular metabolism in activated T cells towards aerobic glycolysis
increases the availability of glycolytic precursors for biosynthetic
reactions [29,40–42]. There is indeed evidence that glycolytic inter-
mediates can be used to generate precursors for protein, nucleotide
and lipid synthesis (through the PPP, the serine biosynthesis path-
way or de novo FAS, for example) [43–45] (Fig. 1A). Nonetheless,
when glycolytic intermediates are used to synthesize biomolecules,
they can no longer generate lactate. In the same manner, when lac-
tate is generated, those speciﬁc glucose-derived carbons cannot be
used in biomolecule synthesis. This explains why proliferating T
cells upregulate glycolysis, but does not clarify why they engage
aerobic glycolysis and why lactate generation takes place. Another
recurrent concept is that lactate generation regenerates NAD+ and
as such, NAD+ homeostasis can be maintained by aerobic glycoly-
sis. In turn, this would help the maintenance of anabolic reactions
that depend on this co-factor to take place. [4,46]. However, since
the same number of regenerated NAD+ molecules had to be used to
generate pyruvate from glucose in the ﬁrst place (Fig. 1A), it is difﬁ-
cult to understand how aerobic glycolysis could result in a net gain
of NAD+ to support other reactions. Even though aerobic glycol-
ysis and “conventional” glycolysis happen simultaneously in cells
[47,48], it is not clear how they can directly contribute to each other.
In fact, from a purely biosynthetic point-of-view, it seems counter-
intuitive that proliferating cells would generate lactate instead of
shuttling pyruvate towards the TCA cycle, where it could be used as
a precursor for amino acid and lipid synthesis, helping to fuel their
biosynthetic demands. In light of these notions, lactate production
and biosynthesis appear to be two  parallel glucose fates. This appar-
ent paradox has been discussed recently along with other currently
suggested advantages for the acquisition of aerobic glycolysis in fast
proliferating cells, such as rapid ATP synthesis or an impact on cell
signaling pathways [5]. Nevertheless, the function of the Warburg
effect in activated T cells remains unclear.
An alternative explanation for the engagement of aerobic gly-
colysis in T cells can be postulated from work done by the group of
Erika Pearce [6]. They demonstrated the importance of glycolysis
in T cell function, by revealing that the glycolytic enzyme glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH), in the absence of
substrate, interfered with the translation of IFN- in Th1 cells [6].
It is thus possible that GAPDH and other glycolytic enzymes could
function as metabolic checkpoints by linking T cell effector func-
tion to glucose availability. Aerobic glycolysis would then serve
to keep GAPDH fully engaged in the glycolytic pathway, prevent-
ing its alternative function as an IFN- translation inhibitor. This
way, even if aerobic glycolysis is an inefﬁcient (albeit fast) ATP-
generating pathway, T cells could use it indirectly to sense their
environment. This would ensure that activation is only achieved
in the presence of an abundant amount of glucose. While this is
the most striking example demonstrated so far for T cells, it is
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nown that most enzymes involved in glycolysis can enter the
ucleus. There, they appear to exert alternative functions (a pro-
ess called ‘moonlighting’) that can directly affect the transcription
nd stability of factors associated with cell proliferation (reviewed
y Boukouris et al. [49]). Thus, in the presence of sufﬁcient amounts
f glucose, maintaining a high glycolytic ﬂux may  allow the cell to
nhance and stabilize the genetic program necessary for prolifera-
ion.
.2. Fatty acid synthesis supports T cell proliferation
Phospholipids and cholesterol are the basic components of the
lasma membrane, which isolates the cell cytoplasm from the
xtracellular environment. After cell division, the cell membrane
urface area of the daughter cells is approximately twice as large as
he surface of the original cell. Consequently, ensuring a sufﬁcient
ipid supply is critical to sustain cell proliferation. Following acti-
ation, T cells switch from FAO to FAS, suggesting that de novo lipid
ynthesis actively supports T cell proliferation and differentiation
10,15,38,45]. In accordance with this, it has been shown that phar-
acological or genetic ACC1 inhibition impairs Th cell induction,
ith the strongest impact on Th17 development [45,50]. Addition-
lly, CD4+ T cell proliferation was impaired by inhibition of FAS
45,51], an outcome that was similarly observed in CD8+ T cells
52]. Lipid synthesis is therefore likely to precede the generation of
ufﬁcient phospholipids to allow for T cell division.
Besides their role in membrane biosynthesis, fatty acids par-
icipate in other processes such as post-translational modiﬁcation
f proteins. Two examples are myristoylation and palmitoylation,
oth of which are processes dependent on the availability of fatty
cids [53]. Accordingly, lipid-dependent protein-modiﬁcations are
lso implicated in the activation of T cells. Palmitoylation of Ras,
or example, was shown to be crucial for its localization to the
ell membrane and, consequently, for efﬁcient TCR activation [54].
ecently it has also been demonstrated that myristoylation (a
rocess that affects protein-lipid interactions and inﬂuences the
ellular localization of proteins) is necessary for the events down-
tream of TCR signaling [55]. In a model of lymphocyte-speciﬁc
-myristoyltransferase (Nmt) deletion (Lck-Cre+Nmt1ﬂ/ﬂNmt2ﬂ/ﬂ),
he secretion of IL-2 and IFN- was impaired upon PMA  stimulation
f CD8+ T cells, suggesting a defect in acquiring an effector pheno-
ype. In a similar fashion, the CD4+ subset failed to upregulate CD69,
n activation marker induced after TCR stimulation [55,56]. Ram-
oldi et al. showed that the lymphocyte-speciﬁc protein tyrosine
inase (Lck) was not myristoylated in Nmt-deﬁcient thymocytes,
nd thus unable to migrate to the cell membrane [55]. As a con-
equence, poor Lck-mediated CD3 phosphorylation may  impede
urther downstream TCR signaling [57–59]. It is currently unclear
f lipid-dependent modiﬁcations of, for example, transcription fac-
ors also inﬂuence their cellular localization, such as migration to
he nucleus, where they would initiate speciﬁc transcriptional pro-
rams. If that were to be the case, an extra link between lipogenic
athways and speciﬁc T cell fates could be establish. Understand-
ng how and if these processes take place will be invaluable for the
ational development of therapies which aim to modulate T cell
unction.
.3. Mitochondria—the powerhouse of the (T) cell
Even though the marked induction of aerobic glycolysis fol-
owing TCR-mediated T cell activation may  imply a lower rate of
XPHOS, it became clear during the last decade that activated T
ells also show a considerable increase in mitochondrial respira-
ion [15,16,60]. Inhibiting mitochondrial OXPHOS in T cells with the
TP synthase inhibitor oligomycin completely abrogated prolifer-
tion, suggesting that ETC activity indeed critically supports T cellunology 28 (2016) 514–524
activation [6]. Indeed, Sena et al. demonstrated that mitochondrial
metabolism by itself can support T cell activation and prolifera-
tion [60]. The presence of pyruvate (which bypasses the glycolytic
pathway and can feed directly into the TCA cycle) was sufﬁcient to
promote the induction of activation markers, IL-2 expression and
proliferation upon CD3/CD28 stimulation in glucose-free medium
[60]. Consistent with this, the addition of a membrane-permeable
form of -ketoglutarate, which can directly enter the TCA cycle,
had a similar effect [60]. Thus, even though Teff cells are highly gly-
colytic, their activation and proliferation can be sustained entirely
by a functional mitochondrial metabolism. In the same study it
was shown that mitochondrial complex III-derived reactive oxygen
species (ROS), which are generated as byproducts of mitochondrial
respiration [61] are essential for T cell activation. Without effective
ROS generation, T cells were unable to acquire an effector pheno-
type and did not become pathogenic in an allergic asthma model. It
was hypothesized in that regard that ROS are necessary for optimal
activation of nuclear factor of activated T cells (NFAT). Since NFAT
binds to the IL-2 promoter [62], induction of this cytokine was also
impaired by the lack of ROS. However, older studies reported that
exposure of human T cells to speciﬁc ROS such as H2O2 prevented
NFAT binding and suppressed IL-2 production [63,64]. Further stud-
ies distinguishing between healthy (apparently fundamental for T
cell activation) and deleterious causing damage to DNA and pro-
teins (reviewed in [65]) doses of ROS will help dissipate such
discrepancies.
One additional way  by which mitochondria support T cell activa-
tion is cytosolic calcium (Ca2+) uptake upon TCR engagement [66].
The mechanisms by which mitochondria can achieve this have been
reviewed by Santo-Domingo and Demaurex [67]. After localizing to
the immune synapse [66,68], mitochondria take up cytosolic Ca2+,
working as “local buffers” to regulate Ca2+ concentrations close to
transmembrane Ca2+ importers. This buffering activity is neces-
sary to sustain Ca2+ inﬂux and consequent calcineurin activation,
a protein that promotes the migration of NFAT into the nucleus
(reviewed by Fracchia et al. [69]). When mitochondrial uptake of
Ca2+ was  blocked, intracellular mobilization of Ca2+ upon CD3  stim-
ulation was  impaired [66]. Interestingly, it was  shown that Ca2+
entry into the cell occurs mainly at places where mitochondria
are in close proximity to the cell membrane, which would explain
the need for their migration to the immune synapse [70]. In addi-
tion, mitochondria have also been shown to release ATP into the
immune synapse upon T cell activation [68]. Mitochondria-derived
ATP acts on extracellular purinergic (P2X) receptors, which function
as ATP-gated Ca2+ channels (reviewed in [71]). Therefore, by releas-
ing ATP into the extracellular space, mitochondria actively promote
enhanced Ca2+ inﬂux into the cell and, as a consequence, foster the T
cell activation process [68]. Thus, mitochondria can regulate T cell
Ca2+ signaling using two  different strategies: actively promoting
Ca2+ import by signaling to purinergic receptors and stabilizing the
Ca2+ inﬂux by acting as a local Ca2+ buffering system. There is now
also evidence that mitochondrial biogenesis is actively upregulated
upon activation [72]. Moreover, these newly synthesized mito-
chondria contained a high abundance of enzymes of the one-carbon
metabolism [72]. This pathway is responsible for providing precur-
sors for the synthesis of purines, NADPH and glutathione [44,73,74].
ShRNA-mediated knockdown of serine hydroxymethyltransferase
2 (SHMT2), a key enzyme of this pathway, in T cells resulted in a
strongly reduced pool of purines and DNA damage (possibly due
to purine/pyrimidine imbalance) [72]. Thus, mitochondrial remod-
eling and the increase of mitochondrial one-carbon metabolism
may actively support cell growth and proliferation following T cell
activation.
So far, the knowledge on the impact of mitochondrial NADH
oxidation in T cell activation and proliferation is still limited.
Without appropriate NADH to NAD+ oxidation, anabolic reactions
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annot take place because NAD+ is required as a co-factor in
any enzymatic reactions. Two elegant studies published recently
ave demonstrated a link between NAD+ availability and cellu-
ar proliferation: Jurkat and 143B (a bone osteosarcoma cell line)
ells treated with ETC inhibitors become dependent on exogenous
AD+-regenerating substrates in order to proliferate [75,76]. Unex-
ectedly, the most acute anti-proliferative factor was not the lack
f mitochondrial ATP synthesis (suggesting that aerobic glycolysis
an sustain ATP production), but the complete inability to synthe-
ize aspartate [75,76]. These ﬁndings were explained by the strong
ependence of the aspartate biosynthetic pathway on the presence
f NAD+. Without aspartate, cells become unable to fully synthesize
roteins and nucleotides and proliferation is limited. Consequently,
t is conceivable that NADH/NAD+ cycling represents also a major
itochondrial function in proliferating T cells.
. Memory T cells—remembering metabolic pathways
Unlike Teff cells, memory T cells do not proliferate and produce
ittle or no cytokines. It is therefore not surprising that memory T
ells, like naïve T cells, display in general a catabolic metabolism,
elying essentially on oxidation of glucose and fatty acids [38,77]
Fig. 2). Yet, memory T cells have several characteristics which dis-
inguish them metabolically from naïve T cells. For example, recent
eports indicate that both CD8+ and CD4+ memory T cells pos-
ess an increased spare respiratory capacity (SRC), mitochondrial
ontent and key ETC proteins [78,79], with the CD4+ subset also
isplaying an enhanced spare glycolytic capacity (such as higher
ytosolic concentration of GAPDH) [78]. Buck et al. showed that
he mitochondria of CD8+ memory T cells exhibit a tightly packed
MM  with a large surface area, which promotes the proximity of
TC complexes [79]. The mitochondria of CD8+ memory T cells
ere elongated due to fusion events between several mitochon-
ria which merge into single, bigger organelles. This facilitated both
he oxidation of NADH generated during metabolic reactions and
he subsequent electron transfer along the ETC complexes. More-
ver, it was shown that the IMM  fusion protein optic atrophy 1
Opa1) was necessary for the fusion events of the IMM  during this
rocess [79,80]. Strikingly, in the absence of Opa1, T cells showed
oor survival when cultured under memory generating conditions
ut not under Teff-promoting conditions, indicating that fusion
f mitochondria is fundamental for CD8+ memory T cell genera-
ion [79]. The in vivo importance of this mitochondria remodeling
as assessed in a model of Listeria monocytogenes, using an OVA
xpressing strain (LmOVA) and adoptive transfer of Opa1−/− OT-I
ells. While the development of CTLs was unaffected by Opa1 deﬁ-
iency, CD8+ memory T cell generation was strongly impaired when
his protein was absent in T cells [79]. Together, these data sug-
est that remodeling the mitochondrial network through fusion
vents is a mechanism to regulate efﬁcient OXPHOS in CD8+ mem-
ry T cells. However, whether a similar process also inﬂuences CD4+
emory T cell generation, remains to be assessed.
Interestingly, the generation of a “futile cycle” of simultaneous
ngagement of FAS and FAO has been demonstrated recently in
D8+ memory T cells [81]. In general, the engagement of such a
utile cycle is prevented by reciprocal regulation of anabolic and
atabolic fatty acid metabolism, which prevents waste of energy. It
as proposed that memory T cells may  activate both processes in
rder to fully meet their metabolic needs and to ensure immediate
etabolic ﬁtness in the event of re-stimulation. Still, further studies
ill be required to better understand how this process is regulatedn T cells.
Taken together, current data suggests that a common charac-
eristic acquired by memory T cells is a higher overall metabolic
tness. In other words, memory T cells appear to be prepared tounology 28 (2016) 514–524 519
re-engage key metabolic reactions on demand. Since memory T
cells are only generated after antigen stimulation, this means that
they possess a TCR that was conﬁrmed to be useful at least once.
For this reason, ensuring that memory T cells are better equipped
for mounting an immune response after re-encounter of their spe-
ciﬁc antigen might be an advantageous strategy to ﬁght pathogens.
Indeed, it was previously suggested that the special metabolic state
of memory T cells is one of the reasons why the immune response
is faster upon the second exposure to a speciﬁc antigen [82].
6. Regulatory T cells—against the (glycolytic) ﬂow
Alternatively to the differentiation of naïve T cells into Teff
cells, CD4+ T cells can acquire a regulatory T cell phenotype. Tregs
expressing the Treg-speciﬁc transcription factor Foxp3 develop
directly in the thymus, but a considerable fraction of Foxp3+ Tregs
is also induced in the periphery from naïve T cells [83]. In contrast
to their thymus-derived counterparts that mainly help to maintain
tolerance to self-antigens, peripherally-derived Foxp3+ Tregs are
believed to be of functional importance for tolerance to food- and
microbiota-derived antigens at mucosal sites [83,84]. In vitro dif-
ferentiated Tregs have been reported to be less glycolytic and more
reliant on FAO and OXPHOS when compared to Teff cells (Fig. 2)
[45,85,86], thus resembling in their general metabolic phenotype
naïve T cells. How different metabolic checkpoints can inﬂuence on
the development of Tregs will be discussed in the next chapters.
Of note, the type 1 regulatory T cell subset (Tr1), which sup-
press T cell responses mainly by the production of IL-10 and do not
express Foxp3 [87], were shown to have a metabolic phenotype
which is similar to Teff cells, displaying a high rate of aerobic gly-
colysis [88]. It is possible that different suppressive mechanisms are
maintained by different metabolic regimes, but this is not clear and
more research will have to be carried out to elucidate this aspect.
7. Metabolism underlying T cell differentiation—key
metabolic checkpoints and pathways
The cytokine milieu in which TCR stimulation occurs deter-
mines the differentiation of naïve CD4+ T cells into one or several
T cell subsets with speciﬁc immunological functions. On the one
hand, Teff cells, classiﬁed by the expression of speciﬁc transcrip-
tion factors and the type of cytokine secreted into Th1, Th2 or
Th17, orchestrate immunity against pathogens, while they can
cause immunopathology upon dysregulation. Tregs, on the other
hand, which keep excessive immune responses in check prevent-
ing autoimmunity and promoting tolerance, can at the same time
interfere with tumor surveillance and effective immunity during
chronic infections. In the last years it has become clear that Th
cells and Tregs must meet certain metabolic criteria in order to
properly differentiate and to carry out their effector functions.
Accordingly, key regulatory molecules exist that help the cell to
sense its metabolic state, controlling if and how activation and dif-
ferentiation takes place. In the next sections we will describe the
function of two important metabolic regulators, mTOR and AMPK
in T cell differentiation. We  will also describe how the modulation
of lipid metabolism can be used as a strategy for modulation of T
cell differentiation.
7.1. Regulation of T cell differentiation by mTOR
mTOR was  ﬁrst discovered as the cellular target of rapamycin
[89], a Streptomyces–derived compound which is currently used
clinically as an immunosuppressive drug [90–92]. The mTOR pro-
tein is a serine/threonine kinase that can be part of two  different
complexes, mTORC1 and mTORC2, depending on the speciﬁc scaf-
520 L. Almeida et al. / Seminars in Immunology 28 (2016) 514–524
Fig. 2. Different T cell subsets and their main metabolic characteristics. The described metabolic proﬁle for Tregs appears to be similar than the one for naïve T cells, with
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dost  glucose and fatty acids being fully oxidized in the mitochondria for the genera
lucose uptake, with most of the glucose-derived pyruvate being excreted as lactate.
n  memory T cells, the mitochondrial mass is increased and a futile cycle of fatty ac
olding proteins associated with it. The existence of distinct mTOR
omplexes allows the same protein to perform different functions
nd to be regulated by different stimuli. mTORC1 integrates signals
hat indicate the presence of nutrients and factors that are neces-
ary for cell growth and division, and links them to the appropriate
etabolic processes. Signals that induce activation of mTORC1
nclude amino acids, oxygen and energy availability as well as
rowth factors [30–34]. Under conditions which are not favorable
or cell growth or division, such as low ATP levels, DNA damage
nd hypoxia, mTORC1 is inhibited and cell growth is impaired [93].
nlike mTORC1, mTORC2 does not respond to nutrient-availability,
ut can instead be stimulated by growth factors and cytokines [93].
There is now good evidence that both mTOR complexes critically
nﬂuence the differentiation of naïve CD4+ T cells. One of the earliest
ndings was the demonstration that rapamycin-treatment, which
ainly affects mTORC1 activity, inhibited Teff cell differentiation
94–96]. Consistent with these ﬁndings, genetic ablation of mTOR in
 cells (which prevents both mTORC1 and mTORC2 signaling) led to
mpaired Th1, Th2 and Th17 development [94]. Yet, T cells specif-
cally lacking mTORC1 activity (due to deletion of the upstream
olecule Rheb) cannot develop into Th1 and Th17 cells, while Th2
ifferentiation is normal [97]. A further study using mice with a
 cell-speciﬁc deletion of Raptor (a scaffolding protein essential
or mTORC1 activity) showed that mTORC1 was required for Th17,
ut not Th1 development [98]. Interestingly, it was suggested that
TORC1 activity may  support Th17 development by the expres-
ion of S6K2, which binds RORt, the master transcription factor
or Th17 cells, and facilitates its transport inside the nucleus[98].
ikewise, Sasaki et al. have shown that activation of S6K1, the clos-
st homolog of S6K2 also downstream of mTORC1, was implicated
xclusively in Th17 development and not on other T cell subsets
99]. Chemical inhibition of mTORC1 with Arctigenin, an active sub-
tance isolated from Arctium lappa L. fruit, equally impaired Th17
nduction, but also the development of Th1 cells [100]. Using a
odel of T cell-speciﬁc deletion of Raptor, another study reported
hat mTORC1 inactivation restricted Th2 development, however
ifferentiation of Th17 or Th1 lineages was not addressed [101].f ATP. During the transition from naïve to effector, there is a major upregulation of
mine uptake also increases and fatty acid synthesis is engaged to nourish activation.
thesis and oxidation has been reported.
Thus, while most studies so far conﬁrm mTORC1 as a prerequisite
for Th17 differentiation, its impact on other Teff lineages is less
clear, and may  strongly depend on the experimental model being
considered. Notably, the role of mTORC2 in Teff cell differentia-
tion turns out to be equally complex. Although it was  consistently
shown that deletion of Rictor (a scaffolding protein essential for
mTORC2 activity) in T cells restrains Th2 differentiation [97,102],
and impaired Th1 development was only reported in one of the
studies [102], while it was not affected in the other report [97]. So
far, the precise reasons for these discrepancies remain unclear.
The relevance of mTOR has also been intensively studied in Treg
development and function. In vitro, naive T cells lacking mTOR
expression spontaneously develop into Tregs after TCR stimula-
tion even in the absence of exogenous TGF- [97]. Surprisingly,
and in contrast to preferential inhibition of mTORC1 by rapamycin,
Rheb-deﬁcient T cells require TGF- to develop into Tregs, indicat-
ing that concomitant inhibition of both mTORC1 and mTORC2 is
required for spontaneous Treg development [97]. Still, the role of
mTOR in Tregs is more complex than initially appreciated, since
Foxp3creRaptorﬂ/ﬂ mice develop general autoimmune responses,
indicating that Tregs fail to exert their protective function when
lacking mTORC1 [103]. Strikingly, in Foxp3cre Raptorﬂ/ﬂ Rictorﬂ/ﬂ
mice, (which lack both mTORC1 and mTORC2 activity in Tregs)
there is an amelioration of this inﬂammatory phenotype. In the
same study, Rictor-deﬁcient Tregs appear to retain their function.
Overall, these data would suggest that mTORC2 activation is dis-
pensable for Treg functionality but its inhibition is required for Treg
development.
In 2010, a study by the group of Giuseppe Matarese demon-
strated that transient mTOR inhibition is necessary for Treg
proliferation, which might explain why Tregs do not proliferate
in vitro even though they do proliferate in vivo [104]. In vitro,
Tregs are exposed to a medium rich in nutrients and cytokines,
which results in constant mTOR activation, leading to defective
Treg proliferation. In vivo, both the concentration of nutrients and
cytokines can vary, and also hormones such as leptin can interfere
with mTOR activation [105]. This exposure to constantly changing
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onditions in the microenvironment might correlate with changing
TOR activity thus enabling Treg proliferation [104]. As a conse-
uence, Tregs may  not have a simple, ﬁxed metabolic state in vivo.
nstead, environmental signals that shape mTOR activity, will in
urn determine their metabolic proﬁle. Hence, under conditions
hat drive high mTOR activity in vivo, Tregs may  adopt a more gly-
olytic and lipogenic metabolic proﬁle in order to proliferate and to
cquire regulatory effector functions. In that respect, a recent study
escribed striking differences in metabolic proﬁles between in vivo
nd in vitro Tregs [106]. Particularly, freshly isolated human Tregs
erformed aerobic glycolysis at a higher rate than naïve T cells and
heir proteome was enriched for glycolytic enzymes, similar to Teff
ells.
More recently it was demonstrated that autophagy, a self-
egradative intracellular process initiated under nutrient stress
onditions, supports the stability and survival ﬁtness of Tregs by
nﬂuencing the mTORC1 signaling pathway [107]. In their study,
ei  et al. generated mice with a Treg-speciﬁc deletion of Atg7,
n essential gene mediating autophagy. Tregs that were unable to
erform autophagy due to their Atg7-deﬁciency exhibit decreased
ineage stability as compared to autophagy-competent Tregs. Upon
doptive transfer, Atg7-deﬁcient Tregs lost Foxp3 expression and
pregulated IFN- or IL-17-production. These defects were asso-
iated with mTORC1 hyperactivation after TCR signaling, c-Myc
ctivation and upregulation of the glycolytic metabolism, together
esulting in a shift towards Teff cell differentiation. Importantly,
nhibition of mTOR by exposing the cells to rapamycin restored
heir lack of stability upon adoptive transfer. Therefore, this study
dds evidence to the hypothesis that autophagy is not merely con-
rolled by mTOR, but that mTOR can also be controlled by autophagy
108].
In addition to its role in T cell activation and Teff versus Treg
ell differentiation, mTOR also inﬂuences cell fate decisions during
hort-lived effector and long-lived memory CD4+ T cell differentia-
ion. Asymmetric mTOR activity in Th cells that replicate following
CR engagement resulted in lower mTORC1 activity in one of the
aughter cells, which was associated with a memory-like pheno-
ype such as higher SRC and higher longevity. This mTORC1-low
opulation was also enriched for Tregs [109], while the population
ith high mTORC1 activity was more likely to become a Teff cell.
nother study done on CD8+ T cells found strikingly similar results,
uggesting that upon TCR stimulation and cell division, the two
aughter cells are intrinsically different in terms of mTOR activ-
ty and metabolic proﬁle [110]. Similarly to the ﬁndings for CD4+
 cells, the mTORC1-low population showed higher mitochondrial
ontent, higher SRC and expressed more anti-apoptotic molecules,
hile the mTORC1-high population displayed increased glycolysis
nd expression of effector molecules [110]. Hence, these ﬁndings
ndicate that the levels of mTOR activity can determine whether
 cell will proceed to develop into an effector or memory pheno-
ype already at an early time point after TCR stimulation and cell
ivision.
.2. A role for AMPK in T cell activation and differentiation
AMP-activated protein kinase (AMPK) is an enzyme that is acti-
ated when the cellular AMP/ATP ratio increases in response to
utrient shortage or other physiological stress, making AMPK an
mportant sensor of the cellular energy levels. Accordingly, the
ctivation of AMPK results in the downregulation of energy con-
uming metabolic pathways such as fatty acid or protein synthesis.
t the same time, pathways that promote energy generation, e.g.
xidation of glucose and fatty acids are upregulated [111,112].
Considering the role of AMPK in inhibiting anabolic reactions,
.g. by its direct ability to interfere with mTOR activation [113,114],
t is likely that AMPK activation will interfere with T cell differentia-unology 28 (2016) 514–524 521
tion. Studies using metformin, which has been originally described
as an activator of AMPK, indeed showed that Th1/Th17 differenti-
ation was  impaired after exposure to this compound [115,116]. In
addition, treating mice with metformin or AICAR, a direct activator
of AMPK, have shown beneﬁcial effects in several inﬂammatory dis-
ease models [117–121]. For example, a decrease in the ratio of Th17
versus Treg upon metformin treatment was  reported in experi-
mental arthritis or colitis models [118]. Interestingly, metformin
treatment in a mouse model of asthma increased the frequency
of Tregs, which was  explained by the ability of AMPK to increase
cellular FAO [85]. However, Gualdoni et al. recently showed that
only AICAR, but not metformin, can boost Treg development in vitro
[122]. Furthermore, the effect of AMPK activation on Tregs was  only
observed in the absence of TGF- and prolonged TCR stimulation
[85,122]. It is thus conceivable that most of the effects of metformin
treatment were mediated by a direct effect on Teff cell development
and function. Additionally, metformin has also been described as
an inhibitor of respiratory complex I [123,124], which may  indicate
that its AMPK-activating effects are more indirect and downstream
of respiratory chain inhibition.
Notably, it has been shown that AMPK is transiently activated
in T cells following TCR stimulation, even when ATP/AMP ratios are
not reduced [125]. Following T cell activation, AMPK appeared to
be activated by Ca2+/calmodulin-dependent protein - (CaMKK),
a kinase that is activated upon intracellular Ca2+ mobilization even
when ATP levels are high [125]. It has been proposed that this
transient AMPK activation allows the cells to prepare for high ATP-
consuming processes that usually take place downstream of TCR
activation [125–127]. In fact, these ﬁndings suggest that T cells do
not rely passively on AMPK in order to maintain cellular homeosta-
sis during energetic stress. Instead, they can activate it on demand
and ensure maximal preparation for the metabolic switch that
normally follows TCR/CD28 activation as noted by Tamas et al.
[125]. Despite these ﬁndings, AMPK appears to be dispensable for
T cell differentiation under normal metabolic conditions, since T
cells which lack a functional AMPK are still able to acquire effec-
tor functions [128,129]. The main consequence of AMPK-deletion
was a lack of metabolic adaptation to nutrient-starvation, which
in turn led to increased cell death under those conditions (Blagih
et al., 2015). Considering that T cells switch between highly vari-
able microenvironments, these ﬁnding suggest that AMPK works
as a “metabolic shield” against suboptimal environmental condi-
tions. This way, AMPK can ensure cell viability under situations
of low nutrient availability, which could be relevant for example in
the highly hypoxic and glucose-deprived tumor microenvironment
[130–132].
7.3. Lipid metabolism tips the balance during T cell differentiation
As we have described above, the induction of cellular lipid
biosynthesis pathways is an integral part of the T cell activation
program. However, we and others have previously observed that
Teff cells and Tregs do not equally rely on FAS for their differen-
tiation [45,50]. While ACC1-deﬁciency, and thus inhibition of de
novo FAS in T cells, strongly restrained Th17 and Th1 differentiation,
Treg development was  enhanced. Moreover, blocking ACC1 activity
even induced a shift from Th17 towards Treg induction under Th17
culture conditions, together suggesting that engagement of FAS is
indispensable for Th17, but not Treg induction [45]. These ﬁndings
may  have important implications for the treatment of inﬂamma-
tory disease, as T cell-speciﬁc deletion of ACC1 or treatment with
ACC-speciﬁc inhibitors protected mice from experimental autoim-
mune encephalomyelitis (EAE), the murine model for multiple
sclerosis [45,50]. Similar results were observed recently in a mouse
model of acute graft-vs-host-disease (GVHD) [51].
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Even though loss of FAS due to ACC-inhibition had an anti-
roliferative effect (most probably due to insufﬁcient fatty acid
upply for phospholipid production) on Th cells, the mechanism
y which FAS-inhibition shifts Th17 differentiation towards Treg
nduction may  involve more speciﬁc cellular processes. In this
egard, it was shown that inhibition of ACC1 in Th17 cells resulted
n changed nuclear localization of RORt and a decreased binding
f this transcription factor to enhancer regions in the Il17a locus
50]. Interestingly, the fatty acid and cholesterol composition of
he cell was shown to modulate RORt binding to different gene
romoters (such as Il17 and Il10) [133]. Even though these ﬁndings
ave not been linked directly to FAS and ACC1 function, it is possi-
le that de novo FAS provides essential lipid precursors which are
hen used in the synthesis of RORt ligands further downstream.
n the absence of such de novo-synthesized lipids, RORt might not
e able to bind to its target regions in genes and Th17 cell cannot
evelop normally. Consistently, intermediates of the cholesterol
etabolism, such as desmosterol or the endogenous cholesterol
erivative oxysterol can act as RORt agonists and enhance Th17
ifferentiation [134,135].
Another explanation for the shift towards Treg induction when
AS is inhibited may  be a higher capacity to take up exogenous fatty
cids, allowing Tregs to compensate for the inhibition of endoge-
ous de novo FAS. This would be in line with studies showing
hat naive T cells activated under Treg cell-inducing conditions
n vitro showed only low rates of glycolysis [85,136] and rather
ake up externally derived fatty acids [45,85]. The results of these
tudies suggest that Tregs, similar to quiescent naïve T cells, rely
n mitochondrial OXPHOS and degradation of fatty acids during
itochondrial FAO. Accordingly, it was demonstrated that Treg
ell development is abrogated upon pharmacological inhibition
f CPT1, the rate limiting enzyme in FAO, suggesting that Tregs
epend on FAO for their development [85]. However, it will be of
mportance to verify this dependence through the use of CPT1/CPT2
oss-of-function genetic models. This is especially critical in light of
ecent ﬁndings in macrophages, suggesting that the widely used
PT1-inhibitor etomoxir might have effects independent of FAO
nhibition. Strikingly, while etomoxir was shown to block alterna-
ive activation in macrophages [137], genetic deletion of Cpt2 (the
soform of CPT present on the IMM)  also abrogated FAO, but did
ot block alternative activation [138]. It is thus possible that Cpt1
s involved in additional cellular functions that are not mediated by
ts role in FAO, but it cannot be ruled out that etomoxir itself has
ff-target effects. In any case, it becomes apparent that data based
xclusively on pharmacological inhibitors should be interpreted
ith care.
Taken together, the metabolic phenotype of Tregs is still poorly
nderstood. It is unknown how it relates to suppressive function
nd, if it does, how it changes during the course of an immune
esponse. Understanding this aspect will be fundamental to deter-
ine whether Tregs can be metabolically manipulated in order
o promote their development and function. This strategy could
e explored therapeutically to help ameliorate diseases such as
utoimmunity and allergy. On the other hand, an opposite strategy
f metabolic-induced Treg suppression might be applicable to pro-
ote the immune-response against tumors or chronic infections.
It should be emphasized that the dependence of T cells on a given
etabolic process in vivo may  be related to the extracellular envi-
onment. For example, when a CD4+ T cell is recruited to (inﬂamed)
eripheral tissue, its metabolic proﬁle might change. These consid-
rations are exempliﬁed by studies demonstrating that alloreactive
ffector T cells preferentially take up fatty acids and rely on FAO
o propagate GVHD [48,139], while on the other hand ex vivo iso-
ated human Tregs were shown to be highly glycolytic [106].Further
esearch will be important to reconcile currently obtained results
oncerning the relevance of FAO and FAS in order to understandunology 28 (2016) 514–524
how the fatty acid metabolism is regulated in Treg versus Teff cell
differentiation and function in vivo.
8. Future perspectives
The appearance of novel, cutting-edge methods and technolo-
gies for the study of metabolism and their application to the
immunology ﬁeld has culminated in a recent burst in the ﬁeld
of immunometabolism. Indeed, it is now possible to follow the
metabolic ﬂux of substrates, both in a more global fashion by using
machines such as extracellular metabolic ﬂux real-time analyzers
and also by individual metabolic proﬁling. Last year saw the divul-
gation of an exciting method that allows for the proﬁling of the
metabolome in real time, being possible to track the changes in
hundreds of individual cellular metabolites [140]. It is now evident
that glucose and lipid metabolism can strongly shape or support T
cell functionality and interference with those pathways may  offer
novel treatment strategies in multiple inﬂammatory disorders [65].
While this review focused on CD4+ and CD8+ T cells with an empha-
sis on T helper cells, metabolic manipulation can also affect other
cell subtypes, including antigen presenting cells. Therefore, in order
to achieve speciﬁcity in such putative therapeutic approaches, it
will be necessary to ﬁrst understand how metabolic manipulation
affects not one, but multiple cell subtypes at a systemic level.
Pharmacological modulators of metabolic enzymes are becom-
ing abundant, allowing us to query for potential effects in
leukocytes after inhibition or activation of certain metabolic routes
in a quick and inexpensive manner. However, due to the complex-
ity which is intrinsic to metabolism, genetic models are a growing
necessity to conﬁrm ﬁndings observed in the immunometabolism
ﬁeld which derive from pharmacological inhibitors.
Even though we  are still some steps away from fully under-
standing the response of immune cells in all the different situations
which can be present in vivo, the knowledge generated in recent
years has already prepared us to better reconsider for example the
methodologies currently being used in the clinics for adoptive T
cell transfers. It is now clear that something as mundane as the
culture medium that the cells are exposed to and the respective
nutrient concentration can dramatically inﬂuence the fate of the T
cells and, consequently, the clinical outcome. Thus, technological
development has paved the way  for the rediscovery of metabolism
by immunologists, and the gain of knowledge in this ﬁeld is now
opening novel therapeutic avenues [141].
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